Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00929903
Other study ID # NCI-2011-01929
Secondary ID NCI-2011-01929CO
Status Completed
Phase Phase 1
First received June 27, 2009
Last updated September 27, 2013
Start date June 2009

Study information

Verified date September 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.


Description:

PRIMARY OBJECTIVES:

I. Estimate the maximum-tolerated dose and/or recommended phase II dose of pazopanib hydrochloride in pediatric patients with relapsed or refractory solid tumors.

II. Define and describe the toxicities of this regimen in these patients. III. Characterize the pharmacokinetics of pazopanib hydrochloride in these patients.

SECONDARY OBJECTIVES:

I. Preliminarily define the antitumor activity of pazopanib hydrochloride within the confines of a phase I study.

II. Evaluate changes in tumor vascular permeability following initiation of pazopanib hydrochloride and correlate these changes with clinical outcome by dynamic contrast-enhanced MRI.

OUTLINE: This is a multicenter study dose-escalation study.

Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients accrued after the maximum-tolerated dose (MTD) of pazopanib hydrochloride has been determined receive pazopanib hydrochloride as an oral suspension.

Some patients undergo dynamic contrast-enhanced MRI at baseline and periodically during study. Blood samples are collected at baseline and periodically during study for pharmacokinetic studies.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 25 Years
Eligibility Inclusion Criteria:

- Diagnosis of 1 of the following:

NOTE: Histologic confirmation not required for intrinsic brain stem cell tumor, optic pathway gliomas, pineal tumors and elevations of cerebrospinal fluid, and serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin.

- Histologically confirmed relapsed or refractory solid tumors at original diagnosis including CNS tumors* (Part 1 and Part 2a)

- Neurologic deficits in patients with CNS tumors must have been relatively stable for = 1 week

- Histologically confirmed soft tissue sarcoma, desmoplastic small round cell tumor, or extraosseus Ewing sarcoma at original diagnosis including the following (Part 2b):

- Tumor in the head, neck, or extremity or fixed within the abdomen or pelvis that it is not sensitive to motion artifact

- No isolated pulmonary metastases

- Disease with no known curative therapy or no therapy proven to prolong survival with acceptable quality of life

- Measurable or evaluable disease (Part 1 and Part 2a)

- Measurable tumor that is = 2 cm in its longest diameter (Part 2b)

- Patients must be:

- > 2 years of age and = 21 years of age (Part 1 and Part 2a)

- > 2 years of age and = 25 years of age (Part 2b)

- Body surface area = 0.48 m^2 (Part 1 and Part 2b)

- For patients with CNS tumors or CNS metastasis, there must be no evidence of new CNS hemorrhage of more than punctate size and/or > 3 foci of punctate hemorrhage on baseline MRI for primary CNS tumors = 14 days prior to study entry

- Karnofsky performance status (PS) 50-100% (> 16 years of age)

- Lansky PS 50-100% (= 16 years of age)

- Platelet count = 100,000/mm^3 (transfusion independent)

- ANC = 1,000/mm^3

- Hemoglobin = 8.0 g/dL (may receive RBC transfusions)

- Creatinine clearance or radioisotope GFR = 70 mL/min OR serum creatinine based on age/gender as follows:

- 0.6 mg/dL (1 to < 2 years of age)

- 0.8 mg/dL (2 to < 6 years of age)

- 1 mg/dL (6 to < 10 years of age)

- 1.2 mg/dL (10 to < 13 years of age)

- 1.5 mg/dL (male ) or 1.4 mg/dL (female) (13 to < 16 years of age)

- 1.7 mg/dL (male) or 1.4 mg/dL (female) ( = 16 years of age)

- Urine protein:creatinine ratio < 1 OR urinalysis negative for protein OR 24-hour urine protein level < 1 g

- Bilirubin = 1.5 times upper limit of normal (ULN)

- ALT = 110 U/L

- PT and PTT = 1.2 times ULN

- INR = 1.2

- Serum albumin = 2 g/dL

- No grade > 1 abnormalities of potassium, calcium, magnesium, or phosphorous

- Supplementation allowed

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Oral contraceptives are not considered effective

- Adequate cardiac function defined as any of the following:

- Shortening fraction of = 27% by echocardiogram

- Ejection fraction of = 50% by gated radionuclide study

- QTc < 450 msec

- No history of myocardial infarction, severe or unstable angina, or peripheral vascular disease or familial QTc prolongation

- Adequate blood pressure defined as = 95th percentile for age, height, and gender

- Known history of well-controlled seizures allowed

- Able to swallow whole tablets (Part 1 and Part 2b)

- No uncontrolled infection

- No evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis

- None of the following conditions within the past 6 months:

- Arterial thromboembolic events, including transient ischemic attack or cerebrovascular accident

- Pulmonary embolism

- Deep vein thrombosis

- Other venous thromboembolic event

- No hemoptysis within the past 6 weeks

- No serious or non-healing wound, ulcer, or bone fracture

- No significant traumatic injury within the past 28 days

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

- No fine-needle aspiration within 48 hours before day 1 of therapy

- Fully recovered from all prior therapy (e.g., chemotherapy, immunotherapy, or radiotherapy)

- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for prior nitrosourea)

- At least 7 days since prior hematopoietic growth factor

- At least 21 days since prior VEGF-Trap

- No prior pazopanib hydrochloride

- At least 7 days since prior VEGF-blocking tyrosine kinase inhibitor or other biological agents

- At least 3 half-lives since prior monoclonal antibody, including bevacizumab

- At least 21 days since any other prior anticancer antibody therapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or = 50% radiotherapy to the pelvis

- At least 6 weeks since prior other substantial bone marrow radiotherapy

- At least 2 months since stem cell transplantation and no evidence of graft-vs-host disease

- Thyroid replacement therapy allowed provided a stable dose has been received for = 4 weeks

- No concurrent medication for cardiac function or hypertension

- Concurrent corticosteroids allowed provided dose is stable or decreasing for > 7 days (for patients enrolled in Part 1 and Part 2a of study)

- No concurrent corticosteroids for patients enrolled in Part 2b of the study

- No other concurrent anticancer agents or radiotherapy

- No other concurrent investigational drugs

- No concurrent enzyme-inducing anticonvulsants

- No concurrent anticoagulation therapy with coumadin and/or low molecular weight heparin

- Prophylactic anticoagulation therapy (i.e., intraluminal heparin) of venous or arterial access devices allowed

- No concurrent aspirin, ibuprofen, or other NSAIDs

- No concurrent drugs metabolized through several of the specific P450 cytochrome isoform including inducers or inhibitors of CYP3A4

- No concurrent drugs with a known risk of torsades de pointes

- At least 28 days since prior major surgical procedure, laparoscopic procedure, or open biopsy

- Port placement or central line placement 48 hours before day 1 of therapy allowed

- No core biopsy within the past 7 days

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Childhood Central Nervous System Choriocarcinoma
  • Childhood Central Nervous System Embryonal Tumor
  • Childhood Central Nervous System Germ Cell Tumor
  • Childhood Central Nervous System Germinoma
  • Childhood Central Nervous System Mixed Germ Cell Tumor
  • Childhood Central Nervous System Teratoma
  • Childhood Central Nervous System Yolk Sac Tumor
  • Choriocarcinoma
  • Glioma
  • Metastatic Childhood Soft Tissue Sarcoma
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Optic Nerve Glioma
  • Recurrent Childhood Brain Stem Glioma
  • Recurrent Childhood Central Nervous System Embryonal Tumor
  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Childhood Visual Pathway Glioma
  • Sarcoma
  • Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Drug:
pazopanib hydrochloride
Given orally
Other:
pharmacological study
Correlative studies

Locations

Country Name City State
United States C S Mott Children's Hospital Ann Arbor Michigan
United States University of Alabama at Birmingham Birmingham Alabama
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Lurie Children's Hospital-Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Baylor College of Medicine Houston Texas
United States Indiana University Medical Center Indianapolis Indiana
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Columbia University Medical Center New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States Seattle Children's Hospital Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum-tolerated dose of pazopanib hydrochloride defined as the maximum dose at which fewer that one-third of patients experience DLT Graded using the NCI CTCAE version 4.0. 28 days Yes
Primary Adverse events according to NCI CTCAE version 4.0 Up to 30 days after completion of study treatment Yes
Primary Pharmacokinetics of pazopanib hydrochloride Summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit). Baseline, days 15, 22, and 27 of course 1 and day 1 of odd courses No
Secondary Overall response to pazopanib hydrochloride according to RECIST criteria The overall response assessment takes into account response in both target and non-target lesions, the appearance of new lesions and normalization of markers. Up to 30 days after completion of study treatment No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00985868 - AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors Phase 1
Completed NCT00253474 - PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase 1
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00459238 - Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants N/A
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Terminated NCT00176540 - Dextromethorphan in Treating Patients With Fatigue Caused by Cancer N/A